Dibyendu Dutta
Overview
Explore the profile of Dibyendu Dutta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dutta D, Black J, Montoya E, Burrow T, Shieh J, McGivern B, et al.
J Med Genet
. 2025 Feb;
PMID: 39904608
Background: Previous reports of distal deletions in chromosome 10q in patients have described distinct facial features combined with other neurodevelopmental abnormalities, including intellectual disability. However, the association of interstitial deletions...
2.
Haroun E, Lim S, Dutta D
Medicina (Kaunas)
. 2024 Oct;
60(10).
PMID: 39459368
In sickle cell disease (SCD), hepatopathy is a cumulative consequence of ischemia/reperfusion (I/R) injury from a vaso-occlusive crisis, tissue inflammation, and iron overload due to blood transfusion. Hepatopathy is a...
3.
Phuna Z, Ashok Kumar P, Haroun E, Dutta D, Lim S
Life Sci
. 2024 Apr;
347:122676.
PMID: 38688384
Antibody-drug conjugates (ADCs) are immunoconjugates that combine the specificity of monoclonal antibodies with a cytotoxic agent. The most appealing aspects of ADCs include their potential additive or synergistic effects of...
4.
Haroun E, Lim S, Dutta D
Hematology
. 2024 Mar;
29(1):2331940.
PMID: 38526293
Background: Endari (L-glutamine) is a conditional amino acid that reduces the frequency of vaso-occlusive crisis (VOC) in sickle cell disease (SCD). Aim: To investigate whether Endari could ameliorate intestinal barrier...
5.
Ashok Kumar P, Ghimire K, Haroun E, Kassab J, Saba L, Gentile T, et al.
Eur J Haematol
. 2023 Oct;
112(3):328-338.
PMID: 37899652
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is increasingly being used in the United States (US) and across the world as a curative therapeutic option for patients with certain high-risk hematologic...
6.
Sahu S, Poplawska M, Lim S, Dutta D
Life Sci
. 2023 Oct;
333:122165.
PMID: 37832631
The development of programmable nucleases to introduce defined alterations in genomic sequences has been a powerful tool for precision medicine. While several nucleases such as zinc-finger nucleases (ZFN), transcriptor activator-like...
7.
Haroun E, Dutta D, Lim S
Br J Haematol
. 2023 Apr;
202(1):184-194.
PMID: 37052197
Voxelotor is an allosteric haemoglobin (Hb) modulator that binds covalently and reversibly to Hb alpha chain to facilitate improved Hb-O affinity and arterial oxygen. It, therefore, reduces the susceptibility of...
8.
Haroun E, Ashok Kumar P, Saba L, Kassab J, Ghimire K, Dutta D, et al.
J Transl Med
. 2023 Apr;
21(1):233.
PMID: 37004099
The intestinal barrier is a complex structure that not only regulates the influx of luminal contents into the systemic circulation but is also involved in immune, microbial, and metabolic homeostasis....
9.
Haroun E, Agrawal K, Leibovitch J, Kassab J, Zoghbi M, Dutta D, et al.
Blood Rev
. 2023 Feb;
60:101054.
PMID: 36805299
Despite the use of high-resolution molecular techniques for tissue typing, chronic graft-versus-host disease (cGVHD) remains a major complication following allogeneic hematopoietic stem cell transplant. cGVHD adversely affects the life-expectancy and...
10.
Nasr D, Ashok Kumar P, Zerdan M, Ghelani G, Dutta D, Graziano S, et al.
Life Sci
. 2022 Oct;
310:121126.
PMID: 36309222
Immunotherapy was first investigated as a therapeutic option for treating cancer more than a century ago. During this period, it has gone through numerous disappointments when the successes obtained in...